T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft ModelZhang, Mei*,†,‡; Graor, Hallie‡,§; Visioni, Anthony‡,§; Strohl, Madeleine*; Yan, Lu*; Caja, Kevin‡,§; Kim, Julian A.*,†,‡,§Journal of Immunotherapy: July/August 2015 - Volume 38 - Issue 6 - p 229–238 doi: 10.1097/CJI.0000000000000078 Basic Studies Buy Abstract Author InformationAuthors Article MetricsMetrics It has been established in murine models that lymph nodes draining a progressively growing tumor contain antigen-specific T cells capable of mediating protective immune responses upon adoptive transfer. However, naturally occurring human tumor-draining lymph nodes (TDLNs) have yet to be fully investigated. In this study, we analyzed TDLNs from patients with stage III melanoma who were undergoing routine lymph node dissection. Following short-term (14 d) culture activation with anti-CD3/anti-CD28 microbeads and expansion in low concentrations of IL-2, the melanoma-draining lymph node (MDLN) cells were ∼60% CD4-activated and ∼40% CD8-activated T cells. The activated MDLN cells demonstrated reactivity in response to overlapping peptides spanning the sequence of 4 different known melanoma antigens MAGEA1, Melan-A/MART-1, NY-ESO-1, and Prame/OIP4, suggesting the presence of melanoma-specific T cells. Coculture of activated MDLN T cells with cancer cells in vitro resulted in preferential apoptosis of human cancer cell lines that were cocultured with T cells with high degree of MHC matching. Adoptive transfer of MDLN T cells with high degree of MHC matching to A375 to mice-bearing human A375 melanoma xenografts resulted in dose-dependent improvement in survival. Although prior human studies have demonstrated the immune responses within melanoma vaccine-draining lymph nodes, this study presents evidence for the first time that naturally occurring human MDLN samples contain melanoma-experienced CD4 and CD8 T cells that can be readily cultured and expanded to mediate protective immune responses both in vitro and in vivo in a human melanoma xenograft model. *Department of Biomedical Engineering, Case Western Reserve University †Case Comprehensive Cancer Center ‡Seidman Cancer Center §Division of Surgical Oncology, University Hospitals Case Medical Center, Cleveland, OH Reprints: Julian Kim, 11100 Euclid Ave, SCC 1205, Cleveland, OH 44106. (e-mail: email@example.com). Received January 26, 2015 Accepted March 19, 2015 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.